Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1562725
PUBLISHER: GlobalData | PRODUCT CODE: 1562725
Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update
PUBLISHED:
PAGES: 115 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
This publication is an update to the report Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030 (November 2021, GDHC232PIDR), which covered the forecast period 2020-30. This updated publication also covers the same forecast period.
GlobalData estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $31.7 billion, representing a compound annual growth rate (CAGR) of 10.6% over the 10-year forecast period.
Major drivers of growth in the PsO market over the forecast period include:
- Steady increase in total diagnosed prevalence across the 7MM
- Launches of seven new pipeline agents: SAR44156, JNJ-2113, sonelokimab, DC-806, orismilast, Piclidenoson, and TAK-279.
- Increased treatment options for mild and moderate patients, a historically undertreated population
The major barriers of growth in the PsO market during the forecast period include -
- Loss of patent protection in the US of biologics, such as Janssen's Stelara (ustekinumab) in 2024 and Cosentyx in 2029, and the subsequent launches of their corresponding biosimilars
- Launch of apremilast generics in 2028 in the US
- Passage of the Inflation Reduction Act (IRA) and other legislature in the US aimed to reduce drug prices.
Scope
- Overview of PsO, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized PsO therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PsO therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PsO treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global PsO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM PsO therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PsO therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Product Code: GDHC292PIDR-7M
Table of Contents
Table of Contents
- About GlobalData
1 Plaque Psoriasis: Executive Summary - Updated April 2024, Based on Events up to April 1, 2024
- 1.1 PsO market to experience conservative growth from 2020-30.
- 1.2 New players to enter a saturated field.
- 1.3 Opportunities remain for undertreated patient populations.
- 1.4 Innovator small molecules dominate the late-stage pipeline
- 1.5 What do physicians think?
2 Introduction
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
3 Disease Overview - Updated April 2024, Based on Events up to April 1, 2024
- 3.1 Etiology and pathophysiology
4 Epidemiology
- 4.1 Disease background
- 4.2 Risk factors and comorbidities
- 4.3 Global and historical trends
- 4.4 Forecast methodology.
- 4.5 Epidemiological forecast for PsO (2020-30)
- 4.6 Discussion
5 Disease Management - Updated April 2024, Based on Events up to April 1, 2024
- 5.1 Diagnosis
- 5.2 Treatment
6 Competitive Assessment - Updated April 2024, Based on Events up to April 1, 2024
- 6.1 Overview
- 6.2 Biosimilars
7 Unmet Needs and Opportunity Assessment - Updated April 2024, Based on Events up to April 1, 2024
- 7.1 Overview
- 7.2 Cost-effective therapies
- 7.3 Efficacious therapies for treatment refractory patients
- 7.4 Lack of innovative topical therapies
- 7.5 Treatment options for mild PsO patients
8 R&D Strategies - Updated April 2024, Based on Events up to April 1, 2024
- 8.1 Development shifts away from injectable biologics
- 8.2 New players enter the late-stage pipeline
- 8.3 Clinical trials design
9 Pipeline Assessment - Updated April 2024, Based on Events up to April 1, 2024
- 9.1 Overview
- 9.2 Promising drugs in clinical development
- 9.3 Other drugs of note
10 Pipeline Valuation Analysis - Updated April 2024, Based on Events up to April 1, 2024
- 10.1 Overview
- 10.2 Competitive assessment
11 Current and Future Players - Updated April 2024, Based on Events up to April 1, 2024
- 11.1 Overview
- 11.2 Deal-making trends
12 Market Outlook - Updated April 2024, Based on Events up to April 1, 2024
- 12.1 Global markets
- 12.2 US
- 12.3 5EU
- 12.4 Japan
13 Appendix
- 13.1 Abbreviations
- 13.2 Methodology
- 13.3 Primary Research - KOLs and payors interviewed for this report.
- 13.4 Bibliography
- 13.5 Primary research - prescriber survey
- 13.6 About the authors
- 13.7 Contact Us
Product Code: GDHC292PIDR-7M
List of Tables
- Table 1: Plaque psoriasis: key metrics in the 7MM
- Table 2: Risk factors and comorbidities for PsO
- Table 3: Classification of PsO by BSA
- Table 4: Treatment guidelines for plaque psoriasis
- Table 5: Top completed deals in PsO market by value, 2018-23
- Table 6: PsO market - global drivers and barriers, 2020-30
- Table 7: Key events impacting sales for PsO in the US, 2020-30
- Table 8: PsO market - drivers and barriers in the US, 2020-30
- Table 9: Key events impacting sales for PsO in the 5EU, 2020-30
- Table 10: PsO market - drivers and barriers in the 5EU, 2020-30
- Table 12: Key events impacting sales for PsO in Japan, 2020-30
- Table 11: PsO market - drivers and barriers in Japan, 2020-30
- Table 13: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
- Figure 1: Global sales forecast by country for PsO in 2020 and 2030
- Figure 2: Analysis of the company portfolio gap in PsO during the forecast period
- Figure 3: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira
- Figure 4: Competitive assessment of the pipeline small molecule drugs benchmarked against the SOC, Otezla
- Figure 5: Biologic and small molecule targets in the Treatment of PsO
- Figure 6: 7MM, lifetime diagnosed prevalence of pediatric PsO (%), boys and girls, Ages <=17 Years, 2020
- Figure 7: 7MM, lifetime diagnosed prevalence of adult PsO (%), men and women, ages >=18 years, 2020
- Figure 8: Sources used for lifetime diagnosed prevalent cases of pediatric PsO
- Figure 9: Sources used and not used for lifetime diagnosed prevalent cases of PsO in adults
- Figure 10: Sources used for lifetime diagnosed prevalent cases of PsO by severity among adults
- Figure 11: Sources used for lifetime diagnosed prevalent cases of PsO with PsA among adults
- Figure 12: 7MM, lifetime diagnosed prevalent cases of PsO, men and women, all ages, 2020 (N)
- Figure 13: Age-specific lifetime diagnosed prevalent cases of PsO, 7MM, men and women, 2020 (N)
- Figure 14: 7MM, sex-specific lifetime diagnosed prevalent cases of PsO, all ages, 2020 (N)
- Figure 15: 7MM, lifetime diagnosed prevalent cases of PsO by severity, men and women, >=18 years, 2020
- Figure 16: 7MM, lifetime diagnosed prevalent cases of PsO with psoriatic arthritis, men and women, >=18 years, 2020 (N)
- Figure 17: Overall treatment algorithm for PsO as approved by EMA
- Figure 18: Unmet needs and opportunities in PsO
- Figure 19: Overview of the development pipeline in PsO
- Figure 20: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PsO in the 7MM during the forecast period
- Figure 21: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira
- Figure 22: Competitive assessment of the pipeline small molecules drugs benchmarked against the SOC, Otezla
- Figure 23: Analysis of the company portfolio gap in PsO during the forecast period
- Figure 24: Global (7MM) sales forecast by country for PsO in 2020 and 2030
- Figure 25: Sales forecast by class for PsO in the US in 2020 and 2030
- Figure 26: Sales forecast by class for PsO in the 5EU in 2020 and 2030
- Figure 27: Sales forecast by class for PsO in Japan in 2020 and 2030
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.